Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$10.62 USD
-0.11 (-1.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARQT 10.62 -0.11(-1.03%)
Will ARQT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Other News for ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Have $5-10? 7 Affordable Stocks That Are About to Breakout.